Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QR01019 potassium
- Development stage
- Phase 1
- Lead developer
- Wuhan Createrna Science and Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
QR01019 potassium is a small molecule antihypertensive agent developed by Wuhan Langlai Pharmaceutical. It is a potassium salt formulation of a novel derivative, likely belonging to the angiotensin II receptor blocker (ARB) class, intended for the treatment of primary hypertension. The drug has been evaluated in a Phase 1 clinical trial (CTR20181075) in China to assess its safety, tolerability, and pharmacokinetics in healthy volunteers, including the impact of food on its absorption profile. As an ARB, its mechanism of action involves the selective antagonism of the angiotensin II receptor type 1 (AT1), which prevents the vasoconstrictive effects of angiotensin II, thereby lowering blood pressure.
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on QR01019 potassium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QR01019 potassium.